IgA Nephropathy clinical trials at UCSF
4 in progress, 3 open to eligible people
Zigakibart in Adults With IgA Nephropathy
open to eligible people ages 18 years and up
Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy
San Francisco, California and other locations
Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
open to eligible people ages 18 years and up
The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function.
San Francisco, California and other locations
Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
open to eligible people ages 18 years and up
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
San Francisco, California and other locations
Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN)
Sorry, in progress, not accepting new patients
This is a phase 3 study to evaluate effects on proteinuria and glomerular filtration rate of sibeprenlimab 400 mg subcutaneously (s.c.) Q 4 weeks in adults with IgAN who are receiving maximally tolerated standard-of-care therapy.
San Francisco, California and other locations
Last updated: